Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (“CMFT”) products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR
Business segments
Jun 2026 · $2.18BThe company’s own SEC segment disclosure.
- Knees$828.9M38%
- SET$586.0M27%
- Hips$562.7M26%
- Technology And Data Bone Cement And Surgical$199.4M9%
Zimmer Biomet (ZBH) reported revenue of $2.09B in Q1 2026 (quarter ended Mar 31, 2026), up 9.3% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $238M (11% of revenue). For the full year FY2025, revenue was $8.23B (+7.2% year on year) and net income $705M. Its largest product in Jun 2026 was Knees at $829M, 38% of the disclosed total, ahead of SET at 27%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Devices
The closest names by size in the same industry